tetano
Editor, Senior Moderator
Am J Trop Med Hyg
. 2022 Feb 3;tpmd210689.
doi: 10.4269/ajtmh.21-0689. Online ahead of print.
Case Report: A Fatal Case of Latent Melioidosis Activated by COVID-19
Uday Gulati[SUP] 1 [/SUP], Ananya C Nanduri[SUP] 1 [/SUP], Prateek Juneja[SUP] 2 [/SUP], David Kaufman[SUP] 1 3 [/SUP], Mindy G Elrod[SUP] 4 [/SUP], Cari B Kolton[SUP] 4 [/SUP], Jay E Gee[SUP] 4 [/SUP], Kristen Garafalo[SUP] 5 [/SUP], David D Blaney[SUP] 4 [/SUP]
Affiliations
Abstract
Melioidosis, endemic in Southeast Asia and Northern Australia, is an uncommon but frequently fatal opportunistic infection caused by the Gram-negative saprophyte Burkholderia pseudomallei. We describe the first reported case of activation of latent melioidosis concurrent with COVID-19-associated lymphopenia and neutropenia in the setting of poorly controlled diabetes. A 43-year-old HIV-positive, diabetic man presented to the emergency department with persistent chills and progressive dyspnea. He was admitted for hypoxia. Chest X-ray showed bilateral parenchymal infiltrates suspicious for COVID-19. Shortly after admission, he became acutely encephalopathic, had a generalized seizure, and was transferred to the intensive care unit after intubation. Further workup showed severe neutropenia and lymphopenia. The patient received empiric antimicrobial coverage and was found to be severe acute respiratory syndrome coronavirus 2 positive. He deteriorated rapidly with refractory shock and persistent hypoxemia, and died 40 hours after admission. Blood cultures and sputum cultures obtained via bronchoalveolar lavage returned positive for Burkholderia pseudomallei. Given confirmed compliance with antiretrovirals, stable CD4 counts, and no recent foreign travel, the patient likely contracted the B. pseudomallei infection from travel to Southeast Asia many years prior and only became symptomatic after succumbing to severe acute respiratory syndrome coronavirus 2 infection. This case highlights the importance of considering activation of latent opportunistic infections by COVID-19 in immunocompromised patients.
. 2022 Feb 3;tpmd210689.
doi: 10.4269/ajtmh.21-0689. Online ahead of print.
Case Report: A Fatal Case of Latent Melioidosis Activated by COVID-19
Uday Gulati[SUP] 1 [/SUP], Ananya C Nanduri[SUP] 1 [/SUP], Prateek Juneja[SUP] 2 [/SUP], David Kaufman[SUP] 1 3 [/SUP], Mindy G Elrod[SUP] 4 [/SUP], Cari B Kolton[SUP] 4 [/SUP], Jay E Gee[SUP] 4 [/SUP], Kristen Garafalo[SUP] 5 [/SUP], David D Blaney[SUP] 4 [/SUP]
Affiliations
- PMID: 35114640
- DOI: 10.4269/ajtmh.21-0689
Abstract
Melioidosis, endemic in Southeast Asia and Northern Australia, is an uncommon but frequently fatal opportunistic infection caused by the Gram-negative saprophyte Burkholderia pseudomallei. We describe the first reported case of activation of latent melioidosis concurrent with COVID-19-associated lymphopenia and neutropenia in the setting of poorly controlled diabetes. A 43-year-old HIV-positive, diabetic man presented to the emergency department with persistent chills and progressive dyspnea. He was admitted for hypoxia. Chest X-ray showed bilateral parenchymal infiltrates suspicious for COVID-19. Shortly after admission, he became acutely encephalopathic, had a generalized seizure, and was transferred to the intensive care unit after intubation. Further workup showed severe neutropenia and lymphopenia. The patient received empiric antimicrobial coverage and was found to be severe acute respiratory syndrome coronavirus 2 positive. He deteriorated rapidly with refractory shock and persistent hypoxemia, and died 40 hours after admission. Blood cultures and sputum cultures obtained via bronchoalveolar lavage returned positive for Burkholderia pseudomallei. Given confirmed compliance with antiretrovirals, stable CD4 counts, and no recent foreign travel, the patient likely contracted the B. pseudomallei infection from travel to Southeast Asia many years prior and only became symptomatic after succumbing to severe acute respiratory syndrome coronavirus 2 infection. This case highlights the importance of considering activation of latent opportunistic infections by COVID-19 in immunocompromised patients.